Cell: Chinese scientists develop a SARS-CoV-2 inactivated vaccine, BBIBP-CorV, animal experiments show effective protective effects
Last Update: 2020-06-17
Search more information of high quality chemicals, good prices and reliable suppliers, visit
, June 9, 2020 /
BIOON/BIOON/-- The 2019 coronavirus pandemic caused by Severe Acute Respiratory Syndrome (SARS-CoV-2) threatens global public healthIn order to prevent and control COVID-19, there is an urgent need to develop a vaccineRevealing the data released by the WHO on June 2nd, 10 vaccines have entered clinical trials worldwide, one of which is in Phase 3 clinical trial s/7, researchers from Beijing Institute of Biological Products Co., Ltd., China Center for Disease Control and Prevention, Beijing Concord Medical College, the State Food and Drug Administration and Tsinghua University published a new study in cell published in cell magazine, presenting a new inactivated candidate vaccine, BBIBP-CorV, which showed that the vaccine can induce a strong protective immune response to SARS-CoV-2Photo Source: Cell
Highlights of the study include:developed an inactivated SARS-CoV-2 candidate vaccine, BBIBP-CorV,, the introduction of high concentrations of neutral antibodies in animal models,two injections of the vaccine (2 ug/times) to protect rhesus monkeys from SARS-CoV-2 infection, and-CoV-2 can be produced efficientlyin the study, researchers reported on the experimental production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV)In animal trials, researchers found that the vaccine induced high levels of neutralizing antibody titer in mice, rats, guinea pigs, rabbits and non-human primates (crab-eating and rhesus monkeys) to provide protection against SARS-CoV-2researchers found that two 2 ug/times of the BBIBP-CorV vaccine against rhesus provided effective protection against the sars-CoV-2 trachea challenge in rhesus monkeys, withsoftwarepark saying no antibody-dependent infections were detectedIn addition, the researchers found that BBIBP-CorV showed efficient productivity and good genetic stability in vaccine production during the production process These results support further evaluation of BBIBP-CorV in the of clinical trials (BioValleyBioon.com) References: Hui Wang et al.
Development of an inactivated vaccine candidate, BBIBP-CorV, with ding dweeddd us against SARS-CoV-2.
Cell 2020 DOI: https://doi.org/10.1016/j.cell.2020.06.008
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.